NCT04705454No Longer Available不适用
Loncastixumab Tesirine (ADCT-402) Expanded Access Program (EAP) for Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma
适应症
试验速览
- 阶段
- 不适用
- 状态
- No Longer Available
研究概览
简要总结
The EAP is for patients with relapsed/refractory diffuse large b-cell lymphoma (R/R DLBCL) that cannot be treated by currently available drugs, cell therapy, or clinical trials. ADC Therapeutics will evaluate patients for approval into the program.
研究设计
- 研究类型
- Expanded Access
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Male or female patient aged 18 years or older
- •Pathologic diagnosis of DLBCL
- •Relapsed/Refractory Diffuse Large B-Cell Lymphoma (R/R DLBCL) that cannot be treated by currently available drugs, cell therapy, or clinical trials
- •Women of childbearing potential must agree to use a highly effective method of contraception from the time of giving informed consent until at least six months after the last dose of loncastuximab tesirine. Men with female partners who are of childbearing potential must agree that they will use a highly effective method of contraception from the time of giving informed consent until at least six months after the patient receives his last dose of loncastuximab tesirine
排除标准
- •Known history of hypersensitivity to or positive serum human Anti-Drug Antibodies to loncastuximab tesirine
- •Total bilirubin >1.5 x upper limit of normal (ULN)
- •Active second primary malignancy other than non-melanoma skin cancers, nonmetastatic prostate cancer, in situ cervical cancer, ductal or lobular carcinoma in situ of the breast, or other malignancy that ADCT Head of Medical Affairs and/or designee, and treating physician agree and document should not be exclusionary
- •Autologous Stem Cell Transplantation (SCT) within 30 days prior to start of loncastuximab tesirine
- •Allogeneic SCT within 60 days prior to start of loncastuximab tesirine
- •Clinically significant third space fluid accumulation (i.e., ascites requiring drainage or pleural effusion that is either requiring drainage or associated with shortness of breath)
- •Lymphoma with active central nervous system involvement at the time of screening, including leptomeningeal disease
- •Breastfeeding or pregnant
- •Major surgery, radiotherapy, chemotherapy or other anti-neoplastic therapy within 14 days prior to starting loncastuximab tesirine, except shorter if approved by ADCT
- •Use of any other experimental medication within 14 days prior to starting loncastuximab tesirine
- •Any other significant medical illness, abnormality, or condition that would, in the treating physician's judgment, make the patient inappropriate to receive loncastuximab tesirine or put the patient at risk
研究者
相似试验
已完成
不适用
Refractory Diffuse Large B-cell LymphomaDiffuse Large B-cell LymphomaNCT03664336Hospices Civils de Lyon104
终止
3 期
Study Comparing Zevalin Regimen With no Further Treatment in Patients With Diffuse Large B-cell Lymphoma.Lymphoma, Large Cell, DiffuseNCT00322218Spectrum Pharmaceuticals, Inc68
招募中
2 期
A-RGEMOX in the Treatment of Early Relapsed/Refractory DLBCLDiffuse Large B-cell Lymphoma RecurrentDiffuse Large B Cell Lymphoma RefractoryNCT06086197Zhejiang Cancer Hospital41
招募中
2 期
ZR2 Followed by Immunochemotherapy in Elderly Patients With Newly-diagnosed DLBCLDiffuse Large B Cell LymphomaNCT05290090Zhejiang Cancer Hospital31
已完成
2 期
BV-CHEP Chemotherapy for Adult T-cell Leukemia or LymphomaLymphomaAdult T-Cell Leukemia/LymphomaLymphatic DiseasesNCT03264131UNC Lineberger Comprehensive Cancer Center16